Iron Supplements Market

On 5 June 2023 the US Food and Drug Administration approved Injectafer, an intravenous iron sold in the United States by American Regent under licence from CSL Vifor, for iron deficiency in adults with heart failure, the first intravenous iron approved for that use. About half of people with chronic heart failure are iron deficient, and the approval turned a deficiency cardiologists often missed into a treatment target. Douglas Insights values the iron supplements market at USD 5.18 billion in 2025 and forecasts USD 7.80 billion by 2035, a compound growth rate of 4.18%. The figure is manufacturer revenue rather than what patients spend at the counter, and the receipt is 352.4 million treated patients in 2025 at USD 14.70 of manufacturer revenue each. Treated patients grow 2.71% a year to 460.4 million as screening spreads through pregnancy, kidney disease and heart failure; revenue per treated patient grows 1.43% a year to USD 16.94 as people who cannot tolerate tablets move to gentler oral forms and to intravenous iron. The figure is published at low coverage and Low confidence, for the reason set out below. The report sits within Douglas Insights coverage of pharmaceuticals and follows the published Douglas Insights research methodology.

What is the iron supplements market?

The iron supplements market covers products that restore or maintain the body’s iron, worth USD 5.18 billion in 2025 at manufacturer value. Over-the-counter oral iron tablets and capsules include ferrous sulphate, ferrous fumarate, ferrous gluconate and newer forms such as iron bisglycinate, sold through pharmacies, supermarkets and mass retail, and online stores. Prescription oral iron and haematinics include iron combined with folic acid, vitamin B12 or vitamin C, and branded products such as iron polymaltose, widely prescribed in India, Europe and Latin America. Oral liquids, drops and chewables serve infants, children and people who cannot swallow tablets. Intravenous iron, including ferric carboxymaltose, iron sucrose, ferric derisomaltose and ferumoxytol, is given in hospitals and clinics and in dialysis centres. Value is split across five indications, iron deficiency and iron deficiency anaemia, pregnancy and maternal health, chronic kidney disease, heart failure, and general wellness, with the overlap declared rather than assumed away. Iron-fortified foods, multivitamins in which iron is a minor ingredient, and blood transfusions sit outside the boundary.

What does the switch to a manufacturer basis change?

This page measures manufacturer revenue, not what a patient hands over at a pharmacy counter or a hospital till, so it sits below any figure built from retail prices: the retail and dispensing margin is not inside it. Douglas Insights model DI-ME-000002, now at version 2, uses that basis across this coverage so one market can be compared with another. Where an older consumer-spend estimate looks larger, the difference is the measuring stick rather than the market.

Version 2 rebalanced where that value sits. Cross-checks against company net sales and Medicare Part B claims put US intravenous iron at USD 1.15 billion, well below the first pass; a retail anchor lifted US oral iron well above it; and a haematinics audit lifted India to USD 327.0 million. The 2025 total barely moved, but 2035 rose to USD 7.80 billion and the rate to 4.18%, because value shifted into products that compound at different speeds.

The coverage label matters as much as the number. Only a minority of the 2025 base is matched to company rows that report an iron revenue line directly; a second band is built from estimates and partial disclosure, and a few companies can be bounded only from above. The remainder is modelled from patient counts, treatment rates and price assumptions rather than tied to a filing, which is why this edition is published in low-coverage mode at Low confidence, and why the company table below reports disclosure rather than share.

How did the Injectafer heart failure approval change the iron supplements market?

The Injectafer heart failure approval opened a large new group of patients to intravenous iron and is the clearest reason iron therapy value concentrates in the hospital rather than the pharmacy. CSL Vifor’s announcement of the approval noted that about every second patient with chronic heart failure has iron deficiency, and that cardiology guidelines in the United States and Europe recommend treating it. American Regent put the number of US adults affected by heart failure with iron deficiency or iron deficiency anaemia at about 2.8 million. It explains why intravenous iron still holds 50% of 2025 value on a fraction of the patients, and the pace at which cardiologists test and treat iron is one of the two swings in the scenarios. It is also why the Injectafer revenue split is the most valuable missing fact in this model, since the same product may be reported by two companies.

What drives iron supplements demand to 2035?

Four drivers carry treated-patient growth of 2.71% a year, and anaemia programmes in emerging markets are the largest by patient count. The World Health Organization estimates anaemia affects about 30% of women aged 15 to 49 worldwide, and iron deficiency causes about half of those cases. Governments in India, Africa and Southeast Asia distribute iron and folic acid tablets to pregnant women, adolescents and children, and private pharmacy sales follow as incomes rise. India’s Anaemia Mukt Bharat programme, launched in 2018, gives weekly iron and folic acid to school children and women of reproductive age, and its screening finds people who then buy privately. Douglas Insights models Asia Pacific rising from USD 1.43 billion in 2025 to USD 2.53 billion in 2035, 5.87% a year and the fastest of the six regions, with Africa next at 5.67%.

Pregnancy and women’s health are the second driver. Most guidelines recommend iron during pregnancy, and screening for iron deficiency rather than only for anaemia is spreading, so each change in national advice moves demand within a single antenatal cycle. A course of oral iron in pregnancy is inexpensive at manufacturer prices, so this driver adds far more to the patient leg than to the revenue leg.

Chronic kidney disease and heart failure are the third driver, and the one that carries value rather than volume: chronic kidney disease alone holds a quarter of 2025 value on a much smaller share of patients. Most dialysis patients receive intravenous iron, and those with kidney disease or heart failure not on dialysis are increasingly tested and treated, with about 2.8 million US adults in the heart failure group. Hospitals also give intravenous iron before planned surgery under patient blood management programmes. A patient moved from tablets to an infusion is worth far more to a manufacturer, which is what sets the revenue-per-patient leg of 1.43% a year.

New formulations are the fourth driver and act entirely on revenue per patient. Many people abandon ferrous sulphate because of stomach side effects, and gentler forms such as iron bisglycinate, sucrosomial iron and ferric maltol sell at several times the price of the salt they replace. That premium is what lifts revenue per treated patient from USD 14.70 to USD 16.94, and what keeps oral iron revenue growing where patient numbers are flat.

What could restrain iron supplements sales?

Cheap generic iron is the first restraint and the reason this market is smaller than its patient count suggests. Ferrous sulphate costs a few cents a day and is bought by governments through low-price tenders, so much of the volume growth in poorer countries reaches the manufacturer as very little revenue. Patient numbers grow fastest in Africa and South Asia while North America, growing slowest at 2.87% a year, still holds the largest block of revenue.

Generic competition in intravenous iron is the second restraint, and it bears on the half of the market carrying the most value. Iron sucrose already faces generics, and generic ferric carboxymaltose is arriving in Europe as patents and data protection expire. That pressure is one reason Europe compounds at only 3.18% a year against 5.87% in Asia Pacific.

Side effects and safety rules are the third restraint. Oral iron often causes constipation and nausea and many users stop early, while intravenous iron carries a small risk of allergic reactions and, for some products, low blood phosphate. Regulators require it to be given where resuscitation facilities are available, which keeps it out of small clinics. Run all three harder and the model’s slower case sets the legs at 1.71% and 0.94%, landing 2035 near USD 6.73 billion.

Which iron supplements segments carry the value?

Intravenous iron leads the iron supplements market with 50% of 2025 value, USD 2.61 billion, and compounds 4.37% a year to USD 4.01 billion, because one course can replace a patient’s iron in one or two visits and is priced per infusion. Prescription oral iron and haematinics grow fastest at 4.45% a year, from USD 940.3 million to USD 1.45 billion, carried by doctor-prescribed combinations in India, Europe and Latin America that sit above generic salts on price. Over-the-counter tablets and capsules hold 22%, USD 1.11 billion, but grow slowest at 3.60% to USD 1.58 billion: they reach the most users by a wide margin, and low manufacturer prices hold that share down. Oral liquids, drops and chewables hold 10%, USD 515.3 million, growing 3.88% to USD 754.0 million on paediatric use.

How do indication and channel split iron supplements?

By indication, iron deficiency and iron deficiency anaemia take the largest block of iron supplements value, chronic kidney disease the second, and general wellness, pregnancy and maternal health, and heart failure divide the rest. By channel, hospitals and clinics take more than half, which is what an intravenous-heavy market looks like from the buying side, with pharmacies second and online stores and supermarkets and mass retail behind them.

Why is intravenous iron taking share from tablets?

Intravenous iron is taking share from tablets because it works faster and avoids the stomach side effects that make many people abandon oral iron. Newer products such as ferric carboxymaltose and ferric derisomaltose give a full dose of 1,000 mg or more in one or two short infusions, where older ones needed five or more visits, each given through an administration set of the kind sized in our precision filter infusion sets market report. Cost, the clinic visit and safety monitoring are the limits, so the 50% of value intravenous iron holds sits with a small minority of treated patients.

Which regions buy the most iron supplements?

North America is the largest regional block at USD 1.96 billion of 2025 manufacturer value and also the slowest-growing at 2.87% a year, reaching USD 2.60 billion in 2035. The United States leads in intravenous iron for kidney disease, heart failure and surgery, but patient numbers are close to flat and generic entry is eroding prices.

Asia Pacific is the growth engine at USD 1.43 billion in 2025 and 5.87% a year to USD 2.53 billion, the fastest of the six regions, led by India’s haematinics market and national anaemia programmes and by China and Southeast Asia. Europe holds USD 959.4 million and grows 3.18% to USD 1.31 billion; it was the first market for ferric carboxymaltose, but generic entry and price controls hold value growth below patient growth.

Africa is the wildcard at USD 267.1 million growing 5.67% to USD 463.8 million, where most supply still moves through public anaemia programmes at tender prices and the private market that carries the value is only forming. Latin America holds USD 320.2 million at 4.60% a year and the Middle East USD 239.2 million at 4.92%.

Who are the leading iron supplements companies?

CSL Vifor, American Regent and Pharmacosmos lead the iron supplements market, all three on intravenous iron rather than tablets, where thousands of brands compete. Douglas Insights publishes no allocated market share for any of them: most of the 2025 base is modelled rather than matched to a company that reports an iron revenue line, and a share table built on that base would read as precision the evidence does not support. Version 2 added estimated revenue for ten further companies, including Sandoz, Viatris, Haleon, Zeria, Sanofi and Norgine, but those rows sit in the long-tail band rather than the floor. The table shows what each company discloses instead.

Advantage rests on clinical evidence in intravenous iron and on brand and distribution in oral iron, where Nature Made, Feroglobin and Floradix compete on gentleness. Indian makers dominate their home haematinics market, which is the largest single reason prescription oral iron grows fastest of the four groups.

How are iron supplements priced?

Manufacturer revenue per treated patient is USD 14.70 in 2025 and reaches USD 16.94 by 2035, a figure blending a few dollars of tablets with a several-hundred-dollar infusion. A month of generic ferrous sulphate costs USD 1 to USD 5 at retail, a month of gentler over-the-counter iron such as bisglycinate USD 8 to USD 25, and a month of branded prescription haematinics in India about USD 2 to USD 6. A course of branded intravenous iron in the United States can cost USD 1,000 to USD 3,000 including administration, and USD 200 to USD 800 in Europe. Those retail bands sit above the manufacturer prices this model counts, and the distance between them is what separates this page from any figure built on consumer spend.

Which rules apply to iron supplements?

Iron supplements fall under two sets of rules, and which one applies decides how a product is priced and who may give it. Over-the-counter oral iron is regulated as a dietary or food supplement in the United States and the European Union, with limits on dose and labelling, while prescription oral iron and all intravenous iron are medicines needing approval from the FDA, the European Medicines Agency or a national regulator. US rules require a child-poisoning warning, because accidental overdose was once a leading cause of poisoning deaths in young children. India regulates supplements under FSSAI nutraceutical rules and prescription iron under drug law. The medicine route is also what makes the intravenous segment measurable, because approvals and reimbursement claims leave a paper trail the supplement aisle does not.

How far could iron supplements reach under each scenario?

The base case takes iron supplements to USD 7.80 billion by 2035, pairing 2.71% growth in treated patients with 1.43% growth in revenue per treated patient for 4.18% a year. The slower case assumes public programmes stall, generic intravenous iron cuts prices faster and cardiologists adopt iron testing slowly, setting the legs at 1.71% and 0.94% for 2.66% a year and about USD 6.73 billion. The faster case assumes wider screening and quicker uptake of intravenous iron in heart failure and pre-surgery care, setting them at 3.71% and 1.93% for 5.70% a year and about USD 9.02 billion. Both branches turn on how much iron revenue the disclosed companies actually carry and on how fast the hospital channel grows against the pharmacy.

Douglas Exclusive: the iron therapy switching tracker

The iron therapy switching tracker records, for 30 countries, the share of iron patients on oral and on intravenous iron by indication, guideline changes, generic intravenous iron launches and public programme coverage, so suppliers see where patients move before the revenue follows. It produced the version 2 rebalance. Related markets are covered in the Nutraceutical Products Market, Dialysis Equipment Market and Health Self Monitoring Technologies Market reports.

Methodology and receipts

The iron supplements model is built bottom-up from treated patients on a manufacturer value basis, and its receipt is 352.4 million treated patients in 2025 at USD 14.70 each. Patients are estimated for 30 countries grouped into four tiers, from anaemia prevalence, births, chronic kidney disease and heart failure prevalence, treatment rates and public programme coverage. Population and births come from World Bank World Development Indicators; anaemia prevalence from World Health Organization data, currently the 2023 release, the oldest input in the build and one reason confidence is held at Low. Company revenue triangulates rather than builds: a matched floor, a long-tail band from estimates and partial disclosure, and ceiling-only rows for suppliers that publish no iron line, with the exact split carried in the Excel model. Version 2 reset four US assumptions and added India-specific prices after the national figures were checked against company net sales, reimbursement claims, a retail anchor and a haematinics audit. Three facts would move the next version: a sourced Injectafer split, Pharmacosmos’s reported iron revenue, and Daiichi Sankyo’s full-year figures.

Sources

1. CSL Limited (CSL Vifor) Injectafer approved in the U.S. for the treatment of iron deficiency in patients with heart failure (2023)
2. American Regent, Inc. INJECTAFER approved in the U.S. for the treatment of iron deficiency in adult patients with heart failure (2023)
3. World Health Organization WHO Global Health Observatory: noncommunicable disease indicators (2026)